Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 2Withdrawn 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 191Thoracic 59Head & Neck 24Gynecologic 10Lymphoid 9Breast 9CNS 6Tumor-Agnostic 4Genitourinary 4Sarcoma 3Endocrine 3Other solid neoplasm 2Other neoplasm 2NET 2Myeloid 1Dermatologic 1

Conditions

Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × sintilimab × Tumor-Agnostic × Clear all
NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Completed
10 enrolled 9 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT04398927 2021-02-04

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Sun Yat-sen University

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT04400851 2020-09-03

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

Sun Yat-sen University

Phase 1 Unknown
18 enrolled
Tumor-Agnostic

Neoplasms

NCT04202601 2019-12-19

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Peking University

Phase 1/2 Unknown
80 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡